Monopar Therapeutics Inc. MNPR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
48/100
Developing

Ranked against 712 peers in Biotechnology

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic … Full MNPR analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 1.00), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.19), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where MNPR ranks in Biotechnology

Monopar Therapeutics Inc. ranks #267 of 713 scored companies in Biotechnology by moat score — the top 37%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
263 Ginkgo Bioworks Holdings, Inc. DNA 48/100 Developing
264 Iovance Biotherapeutics, Inc. IOVA 48/100 Developing
265 MBX Biosciences, Inc. MBX 48/100 Developing
266 Disc Medicine, Inc. IRON 48/100 Developing
267 Monopar Therapeutics Inc. MNPR 48/100 Developing
268 Intellia Therapeutics, Inc. NTLA 48/100 Developing
269 Olema Pharmaceuticals, Inc. OLMA 48/100 Developing
270 Kymera Therapeutics, Inc. KYMR 47/100 Developing
271 LENZ Therapeutics, Inc. LENZ 47/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How MNPR scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 47 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding MNPR's moat

What is Monopar Therapeutics Inc.'s moat score?

Monopar Therapeutics Inc. (MNPR) scores 48 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #267 of 713 scored companies in Biotechnology, the top 37%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (49/100) and its weakest is Capital Efficiency (47/100).

How does Monopar Therapeutics Inc. compare with other Biotechnology companies?

Monopar Therapeutics Inc. ranks #267 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Disc Medicine, Inc. (IRON) at 48 just above it and Intellia Therapeutics, Inc. (NTLA) at 48 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Monopar Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Monopar Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and MNPR scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (47), Resilience (49), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000